I agree. This decline is about the financial situation of the company and not the science. We are in an extremely risk averse environment and no one wants to own a company that might need cash in the next six months because there is no guarantee of the cash materializing or that any cash is going to severely dilute existing shareholders. Obviously with an approved product in Europe and one on the way in the US, I don't think management ever envisioned that they would have to go begging to the capital markets. They should be blamed for this however many, many people did not envision the current crisis getting as bad as it has.
Unfortunately, this market won't be getting better anytime soon but I think if this company can raise enough $$ to survive into the middle of next year until the DIC results are unveiled we shareholders should do okay. (This assumes a parternership for Atryn in the US and approval in the US.)
So the current share price is a screaming buy on the science and probably a good buy based on the financials, IMHO.
News 
Market Data 
Discover 
AI
